Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.
AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m.
As OEB6 increasingly appears in HPAPI and ADC manufacturing, the key question is whether pharmaceutical pipelines actually require a new exposure band — or whether the label is becoming commercial ...
Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.
From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of OSD products are navigating a number of packaging trends and ...
Novo is hoping the platform can help it advance long-lasting injectable formulations to close the gap to rivals in the cardiometabolic arena. Credit: Tada Images/Shutterstock.com. Novo has signed a ...
Ifinatamab deruxtecan was discovered by Daiichi Sankyo. Credit: Pavel Kapysh/Shutterstock.com. Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) ...
The FDA’s approval was supported by data from the PROGRESS study’s cohort 1. Credit: murat photographer/Shutterstock.com. The US Food and Drug Administration (FDA ...
Biopharma firms are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China.
Despite Dr Heidi Overton’s declaration, senators questioned whether the commissioner-elect would challenge erroneous statements from president Trump.
Henlius will oversee the candidates’ research, development, manufacturing and commercialisation worldwide. Credit: Gorodenkoff / Shutterstock.com. Amberstone Biosciences has signed a partnership and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results